The impact of melatonin on the alleviation of cognitive impairment during electroconvulsive therapy: A double-blind controlled trial

Hamdieh, Mostafa; Abbasinazari, Mohammad; Badri, Taleb; Isfeedvajani, Mohsen Saberi; Arzani, Gelareh

doi:10.1016/j.npbr.2017.04.002

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trial reported a statistically significant large effect on global cognitive outcome (MD = 2.95 [1.95, 3.95]; E‐Table 2 ) and short‐term immediate recall after ECT (MD = 0.55 [0.17, 0.93]). 55 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological interventions to diminish cognitive side effects of electroconvulsive therapy: A systematic review and meta‐analysis

Verdijk

Kessel

Oud

et al. 2022

Acta Psychiatr Scand

View full text Add to dashboard Cite

Objective The authors conducted a systematic review and meta‐analysis of pharmacological interventions to diminish cognitive side effects of ECT. Methods Electronic databases of Pubmed, PsycInfo, Embase and Scopus were searched from inception through 1 April, 2021, using terms for ECT (e.g. electroconvulsive therapy), cognitive outcome (e.g. cogni*) and pharmacological intervention (e.g. calcium channel blocker and general terms, like protein). Original studies with humans receiving ECT were included, which applied pharmacological interventions in comparison with placebo or no additive intervention to diminish cognitive side effects. Data quality was assessed using Risk of Bias and GRADE. Random‐effects models were used. PROSPERO registration number was CRD42021212773. Results Qualitative synthesis (systematic review) showed 52 studies reporting sixteen pharmacological intervention‐types. Quantitative synthesis (meta‐analysis) included 26 studies (1387 patients) describing twelve pharmacological intervention‐types. Low‐quality evidence of efficacy was established for memantine (large effect size) and liothyronine (medium effect size). Very low‐quality evidence shows effect of acetylcholine inhibitors, piracetam and melatonin in some cognitive domains. Evidence of no efficacy was revealed for ketamine (very low‐quality), herbal preparations with anti‐inflammatory properties (very low to low‐quality) and opioid receptor agonists (low‐quality). Conclusion Memantine and liothyronine are promising for further research and future application. Quality of evidence was low because of differences in ECT techniques, study populations and cognitive measurements. These findings provide a guide for rational choices of potential pharmacological intervention research targets to decrease the burden of cognitive side effects of ECT. Future research should be more uniform in design and attempt to clarify pathophysiological mechanisms of cognitive side effects of ECT.

show abstract

Section: Resultsmentioning

confidence: 99%

“…One study ( n = 40), reporting very low‐quality evidence on two cognitive outcomes, tested melatonin in patients with MDD. The trial reported a statistically significant large effect on global cognitive outcome (MD = 2.95 [1.95, 3.95]; E‐Table ) and short‐term immediate recall after ECT (MD = 0.55 [0.17, 0.93]) 55 …”

Section: Resultsmentioning

confidence: 99%

Pharmacological interventions to diminish cognitive side effects of electroconvulsive therapy: A systematic review and meta‐analysis

Verdijk

Kessel

Oud

et al. 2022

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial

Sarraf

Badri

Keshvari

et al. 2020

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Naturally occurring melatonin: Sources and possible ways of its biosynthesis

Juhnevica-Radenkova

Moreno

Ikase

et al. 2020

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

According to recent reports, the global market for melatonin is worth 700 million USD in 2018 and would reach 2,790 million USD by 2025, growing at a CAGR of 18.9% during 2019 to 2025. Having regard to the prevalence of sleep and circadian rhythm disorders and a clear tendency to increase the demand for melatonin, and the current lack of alternative green and cost-efficient technologies of its synthesis, the supply of this remedy will not be enough to guarantee melatonin supply and affordability on a global scale. The emergence of naturally occurring melatonin and its isomers in fermented foods has opened an exciting new research area; there are still, however, some obscure points in the efficient microbiological biosynthesis of melatonin. This review summarizes the research progress and recent evidence related to melatonin and its isomers in various foodstuffs. Additionally, one possible way to synthesize melatonin is also discussed. The evidence pointed out that the presence of melatonin and its isomers is not exclusive for grapes and grape-derived products, because it can be also found in sweet and sour cherries. However, different species of both Saccharomyces and non-Saccharomyces yeasts could be used to obtain melatonin and melatonin isomers in the process of alcoholic fermentation biotechnologically. The availability of L-tryptophan has been a key factor in determining the concentration of indolic compounds produced, and the utilization of probiotic lactic acid bacteria could help in the formation of melatonin isomers during malolactic fermentation. These approaches are environmentally friendly alternatives with a safer profile than conventional ones and could represent the future for sustainable industrial-scale melatonin production. K E Y W O R D S alcoholic fermentation, cherry, melatonin, Saccharomyces, yeast 1 ORIGIN AND PHYSIOLOGICAL FUNCTIONS OF MELATONIN Melatonin (MEL), or N-acetyl-5-methoxytryptamine, is a hormone, an indolamine that predominantly appears in plants, microorganisms, and mammals. Primarily, MEL was studied as a neurohormone of the pineal gland, which was discovered for the first time by Lerner, Case, Takahashi, Lee, and Mori (1958). The precursor of this molecule is solely the amino acid L-tryptophan

show abstract

The impact of melatonin on the alleviation of cognitive impairment during electroconvulsive therapy: A double-blind controlled trial

Cited by 4 publications

References 12 publications

Pharmacological interventions to diminish cognitive side effects of electroconvulsive therapy: A systematic review and meta‐analysis

Pharmacological interventions to diminish cognitive side effects of electroconvulsive therapy: A systematic review and meta‐analysis

Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial

Naturally occurring melatonin: Sources and possible ways of its biosynthesis

Contact Info

Product

Resources

About